Organon to Acquire Dermavant including its Innovative …
WEB1 day ago · VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. JERSEY CITY, N.J., September 18, 2024 – Organon (NYSE: OGN), a global healthcare company with a mission to improve ...
Organon makes dermatology play with $1.2bn Dermavant buyout
WEB1 day ago · Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
WEB1 day ago · Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading.
Organon pays up to $1.2B to acquire Dermavant and its steroid …
WEB2 days ago · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in ...
Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · Organon has agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, with an upfront payment of $175 million and a $75 million milestone payment upon regulatory ...
Roivant's Sale Of Dermavant To Organon: Win-Win In Atopic …
WEB13 hours ago · Summary. Organon announced the acquisition of ROIV's Dermavant for $1.2 billion to enhance its dermatology portfolio. The deal includes ROIV's VTAMA cream, which is FDA-approved for plaque ...
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
WEB2 days ago · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...
Roivant sells dermatology spinoff to Organon in deal worth $1.2
WEB1 day ago · Under the terms of the deal, Organon will pay $175 million upfront to acquire Dermavant, plus another $75 million if Vtama’s atopic dermatitis label expansion is approved. That regulatory ...
Roivant dermatology subsidiary to be acquired by Organon
WEB2 days ago · Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis. The medicine is also awaiting ...
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB21 hours ago · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at …
- Some results have been removed